Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea
Lilly’s ObesityWeek 2026 slate: EloraTZP up to 23.3% weight loss in type 2 diabetes, retatrutide cuts sleep apnea events by up to 60.6%, Zepbound data in teens.